Article: Otsuka licenses domestic rights to B-MS' saxagliptin.(Otsuka Pharmaceutical)(Bristol-Myers Squibb Co)(Brief article)

Japan's Otsuka Pharmaceutical has been granted exclusive domestic rights to develop and commercialize US drug major Bristol-Myers Squibb's investigational compound saxagliptin, for the treatment of type 2 diabetes. Otsuka gains rights to the dipeptidyl peptidase-4 inhibitor, which is currently in Phase III development in the USA and Europe, in exchange for ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!